The effect of comorbidities on the sFLT-1:PlGF ratio in preeclampsia

Michael S. Tanner; Deborah de Guingand; Maya Reddy; Saskia Rowson; Daniel L. Rolnik; Mary-Ann Davey; Ben W. Mol; Euan M. Wallace; Fabricio Da Silva Costa; Kirsten R. Palmer

doi:10.1016/j.preghy.2022.06.008

The effect of comorbidities on the sFLT-1:PlGF ratio in preeclampsia

Michael S. Tanner, Deborah de Guingand, Maya Reddy, Saskia Rowson, Daniel L. Rolnik, Mary-Ann Davey, Ben W. Mol, Euan M. Wallace, Fabricio Da Silva Costa, Kirsten R. Palmer

Obstetrics & Gynaecology Monash Health

Research output: Contribution to journal › Article › Research › peer-review

1 Citation (Scopus)

Abstract

Research indicates that soluble fms-like tyrosine kinase 1 (sFLT-1) and placental growth factor (PLGF) have diagnostic and prognostic significance for women with preeclampsia. However, sparse research has studied these biomarkers in women with preexisting comorbidities such as chronic hypertension, diabetes mellitus, systemic lupus erythematosus and chronic kidney disease. We undertook a prospective longitudinal cohort study to compare the sFLT-1: PlGF ratio between women with and without comorbidities who did and did not go on to develop preeclampsia. We found that women with comorbidities may develop preeclampsia with a milder elevation in sFLT-1: PlGF than do women without comorbidities. This has clinical and research implications.

Original language	English
Pages (from-to)	98-100
Number of pages	3
Journal	Pregnancy Hypertension
Volume	29
DOIs	https://doi.org/10.1016/j.preghy.2022.06.008
Publication status	Published - Aug 2022

Keywords

Angiogenic
Comorbidities
Placental growth factor
PlGF
Preeclampsia
sFLT-1
Soluble fms-like tyrosine kinase-1

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.preghy.2022.06.008

Cite this

@article{fd266e81fb664335b57713a49b211aff,

title = "The effect of comorbidities on the sFLT-1:PlGF ratio in preeclampsia",

abstract = "Research indicates that soluble fms-like tyrosine kinase 1 (sFLT-1) and placental growth factor (PLGF) have diagnostic and prognostic significance for women with preeclampsia. However, sparse research has studied these biomarkers in women with preexisting comorbidities such as chronic hypertension, diabetes mellitus, systemic lupus erythematosus and chronic kidney disease. We undertook a prospective longitudinal cohort study to compare the sFLT-1: PlGF ratio between women with and without comorbidities who did and did not go on to develop preeclampsia. We found that women with comorbidities may develop preeclampsia with a milder elevation in sFLT-1: PlGF than do women without comorbidities. This has clinical and research implications.",

keywords = "Angiogenic, Comorbidities, Placental growth factor, PlGF, Preeclampsia, sFLT-1, Soluble fms-like tyrosine kinase-1",

author = "Tanner, {Michael S.} and {de Guingand}, Deborah and Maya Reddy and Saskia Rowson and Rolnik, {Daniel L.} and Mary-Ann Davey and Mol, {Ben W.} and Wallace, {Euan M.} and {Da Silva Costa}, Fabricio and Palmer, {Kirsten R.}",

note = "Funding Information: This research was supported by the Glyn White Research Fellowship and awarded to KRP. MST is supported by an Australian Government Research Training Program (RTP) scholarship. EMW holds an NHMRC Program Grant (APP #1113902). Publisher Copyright: {\textcopyright} 2022 International Society for the Study of Hypertension in Pregnancy",

year = "2022",

month = aug,

doi = "10.1016/j.preghy.2022.06.008",

language = "English",

volume = "29",

pages = "98--100",

journal = "Pregnancy Hypertension",

issn = "2210-7789",

publisher = "Elsevier BV",

}

TY - JOUR

T1 - The effect of comorbidities on the sFLT-1:PlGF ratio in preeclampsia

AU - Tanner, Michael S.

AU - de Guingand, Deborah

AU - Reddy, Maya

AU - Rowson, Saskia

AU - Rolnik, Daniel L.

AU - Davey, Mary-Ann

AU - Mol, Ben W.

AU - Wallace, Euan M.

AU - Da Silva Costa, Fabricio

AU - Palmer, Kirsten R.

N1 - Funding Information: This research was supported by the Glyn White Research Fellowship and awarded to KRP. MST is supported by an Australian Government Research Training Program (RTP) scholarship. EMW holds an NHMRC Program Grant (APP #1113902). Publisher Copyright: © 2022 International Society for the Study of Hypertension in Pregnancy

PY - 2022/8

Y1 - 2022/8

N2 - Research indicates that soluble fms-like tyrosine kinase 1 (sFLT-1) and placental growth factor (PLGF) have diagnostic and prognostic significance for women with preeclampsia. However, sparse research has studied these biomarkers in women with preexisting comorbidities such as chronic hypertension, diabetes mellitus, systemic lupus erythematosus and chronic kidney disease. We undertook a prospective longitudinal cohort study to compare the sFLT-1: PlGF ratio between women with and without comorbidities who did and did not go on to develop preeclampsia. We found that women with comorbidities may develop preeclampsia with a milder elevation in sFLT-1: PlGF than do women without comorbidities. This has clinical and research implications.

AB - Research indicates that soluble fms-like tyrosine kinase 1 (sFLT-1) and placental growth factor (PLGF) have diagnostic and prognostic significance for women with preeclampsia. However, sparse research has studied these biomarkers in women with preexisting comorbidities such as chronic hypertension, diabetes mellitus, systemic lupus erythematosus and chronic kidney disease. We undertook a prospective longitudinal cohort study to compare the sFLT-1: PlGF ratio between women with and without comorbidities who did and did not go on to develop preeclampsia. We found that women with comorbidities may develop preeclampsia with a milder elevation in sFLT-1: PlGF than do women without comorbidities. This has clinical and research implications.

KW - Angiogenic

KW - Comorbidities

KW - Placental growth factor

KW - PlGF

KW - Preeclampsia

KW - sFLT-1

KW - Soluble fms-like tyrosine kinase-1

UR - http://www.scopus.com/inward/record.url?scp=85134331159&partnerID=8YFLogxK

U2 - 10.1016/j.preghy.2022.06.008

DO - 10.1016/j.preghy.2022.06.008

M3 - Article

C2 - 35843203

AN - SCOPUS:85134331159

SN - 2210-7789

VL - 29

SP - 98

EP - 100

JO - Pregnancy Hypertension

JF - Pregnancy Hypertension

ER -

The effect of comorbidities on the sFLT-1:PlGF ratio in preeclampsia

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Improving perinatal outcomes.

Cite this

The effect of comorbidities on the sFLT-1:PlGF ratio in preeclampsia

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Projects

Improving perinatal outcomes.

Cite this